Century TherapeuticsIPSC
About: Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
Employees: 165
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
400% more call options, than puts
Call options by funds: $10K | Put options by funds: $2K
190% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 10
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
7% more funds holding
Funds holding: 67 [Q3] → 72 (+5) [Q4]
4.08% less ownership
Funds ownership: 46.89% [Q3] → 42.81% (-4.08%) [Q4]
46% less capital invested
Capital invested by funds: $67.9M [Q3] → $36.8M (-$31.1M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Mitchell Kapoor 30% 1-year accuracy 54 / 179 met price target | 663%upside $5 | Buy Reiterated | 22 Jan 2025 |
Piper Sandler Edward Tenthoff 23% 1-year accuracy 9 / 39 met price target | 510%upside $4 | Overweight Maintained | 30 Dec 2024 |
Financial journalist opinion
